The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
U.S. Department of Health and Human Services
Health Resources and Services Administration

A-Z Index  |  Questions?   |  HRSA Mobile

  • Print this
  • Email this

Classification for Treatment Purposes

Classification of Hansen's Disease (leprosy) is based on clinical evaluation, skin smears from several sites and ideally at least an initial biopsy. The Ridley-Jopling classification of the disease is the one usually used in the United States. The following terms denote disease ranging from early localized (I) to generalized (LL):

  • indeterminate (I) ,
  • tuberculoid (TT) ,
  • borderline tuberculoid (BT) ,
  • mid - borderline (BB) ,
  • borderline lepromatous (BL) and
  • lepromatous (LL) .

While this classification gives one considerable information about the disease in an immunologic sense, the use of the World Health Organization's limited duration multidrug therapy has led to the widespread adoption of the WHO classification. This includes only the following:

  • single lesion paucibacillary (SLPB)
  • paucibacillary (PB) , i.e., those with 2 - 5 lesions, and
  • multibacillary (MB) with six or more lesions.

In the U.S., generally only the terms paucibacillary and multibacillary are used when discussing drug regimens. Paucibacillary patients are those who are skin smear negative and no evidence of more advanced disease on biopsy.   Multibacillary patients are those who are skin smear positive and/or have a biopsy indicating more advanced disease. Generally PB disease is equivalent to I, TT and BT disease in the Ridley-Jopling classification, and MB is equivalent to BB, BL and LL disease.